Latest research on Herceptin

A recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein. Produced in CHO cell culture.*

Herceptin indications

For the early stage, data such as annual transition probabilities were based on Smith et al. (2007), where trastuzumab’s effect on overall survival in Belgian patients with HER2+ breast cancer was investigated after a median follow-up of 2 years in the Herceptin Adjuvant (HERA) study [6]. [source, 2016]
trastuzumab emtansine (T-DM1) is an ADC consisting of the anti-HER2 mAb trastuzumab (Herceptin) and the maytansinoid DM1 has been administered safely at therapeutically effective doses, despite HER2 being expressed on some normal tissues [95–98]. [source, 2015]
Although the exact mechanisms by which Herceptin is capable of inhibiting HER-2 are not yet completely understood, some of its effects have been observed, both in vitro and in vivo, such as diminished receptor signaling, induction of apoptosis, inhibition of angiogenesis and inhibition of DNA repair [45]. [source, 2015]
In a famous example, which involved stratifying sub-population of trastuzumab-receiving patients, both NICE (The National Institute for Health and Care Excellence) and SMC (Scottish Medicines Consortium) did not consider Herceptin to be cost-effective for the large gastric cancer population initially, but once the HER2 overexpression (IHC 3+) subgroup was defined, the drug was immediately considered as cost-effective. [source, 2015]
For other markers, the level of expression is the best indication for or against efficacy (e.g. high levels of HER2 expression and Herceptin). [source, 2015]
Herceptin was then immobilized on the surface of GNP (GNP–Her) to enrich the anticancer effects of chemotherapeutic agents. [source, 2015]
After the reaction of the free amine groups of GNP with Herceptin, absorption at 1,648 cm−1 and 1,540 cm−1 appeared, due to the amide groups of GNP–Her, proving the effective immobilization of Herceptin over the GNPs. [source, 2015]
Figure 10 shows that Herceptin is an effective antibody, binding specifically to the HER2-bearing breast tumor cells. [source, 2015]
GNP–Her had no cytotoxic effect on the control cells (FB) compared to the target cells (SK-BR3) and was internalized selectively into the target cells (SK-BR3); the free Herceptin was delivered into the cytoplasm, which induced acute apoptosis. [source, 2015]
A phase II trial revealed that Herceptin exerted a therapeutic effect on CRC, although the low overexpression rate of HER-2 (8.0%) in advanced CRC limited the efficacy of the drug (17). [source, 2015]